GlaxoSmithKline Pharmaceuticals Ltd GLAXO.NS
₹2,958.10 ₹19.20 (0.65%) 1D
Last Updated: Sep 04, 12:00 AM·NSE
Pricing for IN stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
GLAXO.NS Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, GlaxoSmithKline Pharmaceuticals Ltd is classified as halal.
HALAL
Report Source: undefined Quarter Report
GlaxoSmithKline Pharmaceuticals Ltd. Stock Analysis GLAXO.NS
India Health Care Mid Cap GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 3,113 full-time employees. The firm is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The firm has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The firm's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The firm's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS) Chart
Financial Metrics & Statements of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS)
FAQ's for GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS)
- As of September 2026, GlaxoSmithKline Pharmaceuticals Ltd GLAXO.NS is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes GlaxoSmithKline Pharmaceuticals Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in GlaxoSmithKline Pharmaceuticals Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of GlaxoSmithKline Pharmaceuticals Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of GlaxoSmithKline Pharmaceuticals Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of GlaxoSmithKline Pharmaceuticals Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
